2McLaughlin P, White C A, Grillo-Lopez A J,et al. Clinical status and optimal use of rituximab for B-cell lymphomas [J]. Oncology (Huntingt), 1998, 12 ( 12 ) :1763-1769.
3Boye J, Elter T, Engert A. An overview of the current clinical use of the anti - CD30 monoclonal antibody rituximab [J]. Ann Oncol,2003, 14(4 ) :520-535.
5Plosker G L, Figgitt D P. Rituximab: a review of its use in non - Hodgkin's lymphoma and chronic lymphocytic leukaemia [J]. Drugs,2003, 63 ( 8 ): 803-843.
6Economopoulos T, Fountzilas G, Pavlidis N,et al. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma[J].Hematol J,2003,4(2):110-115.
8Dillman R O. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab[J]. Semin Oncol, 2003, 30( 4 ) :434-447.
9Bueno J, Ramil C, Somoza I, et al. Treatment of monomorphio B-cell lymphoma with rituximab after liver transplantation in a child [J].Pediatr Transplant, 2003, 7 ( 2 ): 153-156.
10Culic S, Culic V, Armanda V, et al. AntiCD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large Bcell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl [J]. Pediatr HematolOncol, 2003, 20( 4 ) :339-344.
